Newsfeed : ACT UP Letter Asks U.S. Senate to Negotiate Sovaldi Price Cut

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Newsfeed » August 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 29, 2014

ACT UP Letter Asks U.S. Senate to Negotiate Sovaldi Price Cut

The New York chapter of the AIDS Coalition to Unleash Power (ACT UP) has sent a letter to the U.S. Senate Finance Committee asking it to negotiate with Gilead Sciences to reduce the price of Sovaldi (sofosbuvir), according to an ACT UP statement.

In the United States, the hepatitis C drug costs about $1,000 per pill, or nearly $84,000 for a full course of treatment. ACT UP seeks a price reduction of at least 90 percent. Gilead has made nearly $5.8 billion in Sovaldi sales since the start of this year.

ACT UP argues that the drug’s current pricing is unfair, will ultimately cost billions of dollars in unnecessary U.S. health care spending and also will seriously limit the number of people able to access the treatment.

In addition to seeking price negotiations, the letter also proposes the Senate initiate a patent buyout. If both approaches fail, ACT UP suggests, the Senate should then waive Gilead’s Sovaldi patent under the “government use” statute.

In the United States, more than 1 million people have HIV and more than 3 million people have the hepatitis C virus (HCV). About 225,000 to 330,000 Americans are coinfected with both.

To read the statement, click here. To read the letter, click here.

Search: ACT UP, New York, Gilead Sciences, hepatitis C, HCV, Sovaldi, pricing, Senate, coinfection

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.